Biologics (Biosimilar) Market Report

China Biologics (Biosimilar) Industry Market Research Report 2023-2029

  • POSTDATE：Oct 08, 2023
  • PAGES：223
  • REPORT CODE：GMM1837479
  • REPORT SUMMARY
  • TABLE OF CONTENTS

  • A biosimilar product is a biologic product that is approved based on demonstrating that it is highly similar to an FDA‐approved biologic product, known as a reference product, and has no clinically meaningful differences in terms of safety and effectiveness from the reference product.

    This report elaborates on the current development of the Biologics (Biosimilar) industry thoroughly based on the international market dynamics and China's market situation.

    For a start, the report provides an in-depth analysis of the current market situation through three different aspects - by region, by type and by application, which includes market distribution of different types and applications, import and export analysis of major regions, development trends of different types of products in each region, market opportunities and market restrains of different applications.

    Secondly, this report lists the major players in the industry, displaying their market positions and strengths and weaknesses of their products, picturing the current competitive situation of the whole market. 

    Last but not least, the report analyzes and predicts the investment prospects and risks in the industry on the basis of industry data, combined with experts' opinions and suggestions.

    By Player:

    • Gelgen Biopharma

    • Mylan

    • Sanofi

    • Biotech Pharma

    • Sandoz

    • Merck

    • Johnson & Johnson

    • Hospira

    • Lilly

    • 3sbio

    • AbbVie

    • Pfizer

    • Novartis

    • Amgen

    • Roche

    • CP Guojian Pharmacy

    By Type:

    • Recombinant Non-glycosylated Proteins

    • Recombinant Glycosylated Proteins

    By Application:

    • Chronic and Autoimmune Disorders

    • Blood Disorders

    • Others

    • Oncology

    • Growth Hormonal Deficiency

    By Research Region:

    • North China

    • Central China

    • South China

    • East China

    • Northeast China

    • Southwest China

    • Northwest China

  • TABLE OF CONTENT

    Chapter 1 China Biologics (Biosimilar) Market Overview 2018-2029

    • 1.1 China Biologics (Biosimilar) Industry Development Overview

    • 1.2 China Biologics (Biosimilar) Industry Development History

    • 1.3 China Biologics (Biosimilar) Industry Market Size (2018-2029)

    • 1.4 China Biologics (Biosimilar) Market Analysis by Type from Production Side

      • 1.4.1 China Biologics (Biosimilar) Production Volume, Production Value and Growth Rate of Recombinant Non-glycosylated Proteins (2018-2029)

      • 1.4.2 China Biologics (Biosimilar) Production Volume, Production Value and Growth Rate of Recombinant Glycosylated Proteins (2018-2029)

    • 1.5 China Biologics (Biosimilar) Market Analysis by Application from Consumption End

      • 1.5.1 China Biologics (Biosimilar) Sales Volume, Sales Value and Growth Rate of Chronic and Autoimmune Disorders (2018-2029)

      • 1.5.2 China Biologics (Biosimilar) Sales Volume, Sales Value and Growth Rate of Blood Disorders (2018-2029)

      • 1.5.3 China Biologics (Biosimilar) Sales Volume, Sales Value and Growth Rate of Others (2018-2029)

      • 1.5.4 China Biologics (Biosimilar) Sales Volume, Sales Value and Growth Rate of Oncology (2018-2029)

      • 1.5.5 China Biologics (Biosimilar) Sales Volume, Sales Value and Growth Rate of Growth Hormonal Deficiency (2018-2029)

    • 1.6 China Biologics (Biosimilar) Market Analysis by Region

      • 1.6.1 North China Biologics (Biosimilar) Market Size and Growth Rate from 2018-2029

      • 1.6.2 Central China Biologics (Biosimilar) Market Size and Growth Rate from 2018-2029

      • 1.6.3 South China Biologics (Biosimilar) Market Size and Growth Rate from 2018-2029

      • 1.6.4 East China Biologics (Biosimilar) Market Size and Growth Rate from 2018-2029

      • 1.6.5 Northeast China Biologics (Biosimilar) Market Size and Growth Rate from 2018-2029

      • 1.6.6 Southwest China Biologics (Biosimilar) Market Size and Growth Rate from 2018-2029

      • 1.6.7 Northwest China Biologics (Biosimilar) Market Size and Growth Rate from 2018-2029

    Chapter 2 China Biologics (Biosimilar) Industry Development Environment

    • 2.1 Industry Development Environment Analysis

      • 2.1.1 Industry Technological Progress Analysis

      • 2.1.2 Industrial Organizational Innovation Analysis

      • 2.1.3 Changes in Social Habits

      • 2.1.4 Alterations in Government Policies

      • 2.1.5 Impact of Economic Globalization

    • 2.2 Domestic and Foreign Industry Competition Analysis

      • 2.2.1 Comparative Analysis on Biologics (Biosimilar) Market Status and Competition at home and abroad in 2023

      • 2.2.2 China Biologics (Biosimilar) Market Status and Competition Analysis in 2023

      • 2.2.3 China Biologics (Biosimilar) Market Concentration Analysis in 2023

    • 2.3 Problems and Countermeasures in the development of China Biologics (Biosimilar) Industry

      • 2.3.1 Industry Development Constraints

      • 2.3.2 Industry Development Considerations

      • 2.3.3 Suggestions on Industry Development Measures

      • 2.3.4 Development Strategies for SMEs

    • 2.4 Influence of COVID-19 Outbreak on Biologics (Biosimilar) Industry Development

    Chapter 3 Biologics (Biosimilar)Industry Chain Analysis

    • 3.1 Biologics (Biosimilar) Industry Chain

    • 3.2 Biologics (Biosimilar) Upstream Industry Analysis

      • 3.2.1 Upstream Industry Development Status

      • 3.2.2 Upstream Industry Development Forecast

      • 3.2.3 Impact of Upstream Industry on the Biologics (Biosimilar) Market

    • 3.3 Biologics (Biosimilar) Downstream Industry Analysis

      • 3.3.1 Downstream Industry Development Status

      • 3.3.2 Downstream Industry Development Forecast

      • 3.3.3 Impact of Downstream Industry on the Biologics (Biosimilar) Market

    Chapter 4 China Biologics (Biosimilar) Market, by Type

    • 4.1 China Biologics (Biosimilar) Market Trend, by Type

    • 4.2 Product Types of Major Suppliers

    • 4.3 Competitive Landscape of Major Types

    • 4.4 China Biologics (Biosimilar) Total Production Volume and Growth Rate from Production Side

    • 4.5 China Biologics (Biosimilar) Production Volume and Growth Rate, by Type

      • 4.5.1 China Biologics (Biosimilar) Production Volume and Growth Rate of Recombinant Non-glycosylated Proteins

      • 4.5.2 China Biologics (Biosimilar) Production Volume and Growth Rate of Recombinant Glycosylated Proteins

    Chapter 5 China Biologics (Biosimilar) Market, by Application

    • 5.1 Downstream Market Overview

    • 5.2 Competitive Landscape of Major Applications

    • 5.3 Market Potential Analysis, by Application

    • 5.4 China Biologics (Biosimilar) Total Market Size and Growth Rate from Consumption End

    • 5.5 China Biologics (Biosimilar) Market Size and Growth Rate, by Application

      • 5.5.1 China Biologics (Biosimilar) Market Size and Growth Rate of Chronic and Autoimmune Disorders

      • 5.5.2 China Biologics (Biosimilar) Market Size and Growth Rate of Blood Disorders

      • 5.5.3 China Biologics (Biosimilar) Market Size and Growth Rate of Others

      • 5.5.4 China Biologics (Biosimilar) Market Size and Growth Rate of Oncology

      • 5.5.5 China Biologics (Biosimilar) Market Size and Growth Rate of Growth Hormonal Deficiency

    Chapter 6 China Biologics (Biosimilar) Market, by Region

    • 6.1 China Biologics (Biosimilar) Production Volume and Production Value, by Region

    • 6.2 China Biologics (Biosimilar) Sales Volume and Sales Value, by Region

    Chapter 7 North China Biologics (Biosimilar) Market Analysis

    • 7.1 North China Biologics (Biosimilar) Market, by Type

    • 7.2 North China Biologics (Biosimilar) Market, by Application

    Chapter 8 Central China Biologics (Biosimilar) Market Analysis

    • 8.1 Central China Biologics (Biosimilar) Market, by Type

    • 8.2 Central China Biologics (Biosimilar) Market, by Application

    Chapter 9 South China Biologics (Biosimilar) Market Analysis

    • 9.1 South China Biologics (Biosimilar) Market, by Type

    • 9.2 South China Biologics (Biosimilar) Market, by Application

    Chapter 10 East China Biologics (Biosimilar) Market Analysis

    • 10.1 East China Biologics (Biosimilar) Market, by Type

    • 10.2 East China Biologics (Biosimilar) Market, by Application

    Chapter 11 Northeast China Biologics (Biosimilar) Market Analysis

    • 11.1 Northeast China Biologics (Biosimilar) Market, by Type

    • 11.2 Northeast China Biologics (Biosimilar) Market, by Application

    Chapter 12 Southwest China Biologics (Biosimilar) Market Analysis

    • 12.1 Southwest China Biologics (Biosimilar) Market, by Type

    • 12.2 Southwest China Biologics (Biosimilar) Market, by Application

    Chapter 13 Northwest China Biologics (Biosimilar) Market Analysis

    • 13.1 Northwest China Biologics (Biosimilar) Market, by Type

    • 13.2 Northwest China Biologics (Biosimilar) Market, by Application

    Chapter 14 Company Profiles

      • 14.1 Gelgen Biopharma

        • 14.1.1 Gelgen Biopharma Company Profile

        • 14.1.2 Gelgen Biopharma Biologics (Biosimilar) Market Performance

        • 14.1.3 Product&Service Introduction

      • 14.2 Mylan

        • 14.2.1 Mylan Company Profile

        • 14.2.2 Mylan Biologics (Biosimilar) Market Performance

        • 14.2.3 Product&Service Introduction

      • 14.3 Sanofi

        • 14.3.1 Sanofi Company Profile

        • 14.3.2 Sanofi Biologics (Biosimilar) Market Performance

        • 14.3.3 Product&Service Introduction

      • 14.4 Biotech Pharma

        • 14.4.1 Biotech Pharma Company Profile

        • 14.4.2 Biotech Pharma Biologics (Biosimilar) Market Performance

        • 14.4.3 Product&Service Introduction

      • 14.5 Sandoz

        • 14.5.1 Sandoz Company Profile

        • 14.5.2 Sandoz Biologics (Biosimilar) Market Performance

        • 14.5.3 Product&Service Introduction

      • 14.6 Merck

        • 14.6.1 Merck Company Profile

        • 14.6.2 Merck Biologics (Biosimilar) Market Performance

        • 14.6.3 Product&Service Introduction

      • 14.7 Johnson & Johnson

        • 14.7.1 Johnson & Johnson Company Profile

        • 14.7.2 Johnson & Johnson Biologics (Biosimilar) Market Performance

        • 14.7.3 Product&Service Introduction

      • 14.8 Hospira

        • 14.8.1 Hospira Company Profile

        • 14.8.2 Hospira Biologics (Biosimilar) Market Performance

        • 14.8.3 Product&Service Introduction

      • 14.9 Lilly

        • 14.9.1 Lilly Company Profile

        • 14.9.2 Lilly Biologics (Biosimilar) Market Performance

        • 14.9.3 Product&Service Introduction

      • 14.10 3sbio

        • 14.10.1 3sbio Company Profile

        • 14.10.2 3sbio Biologics (Biosimilar) Market Performance

        • 14.10.3 Product&Service Introduction

      • 14.11 AbbVie

        • 14.11.1 AbbVie Company Profile

        • 14.11.2 AbbVie Biologics (Biosimilar) Market Performance

        • 14.11.3 Product&Service Introduction

      • 14.12 Pfizer

        • 14.12.1 Pfizer Company Profile

        • 14.12.2 Pfizer Biologics (Biosimilar) Market Performance

        • 14.12.3 Product&Service Introduction

      • 14.13 Novartis

        • 14.13.1 Novartis Company Profile

        • 14.13.2 Novartis Biologics (Biosimilar) Market Performance

        • 14.13.3 Product&Service Introduction

      • 14.14 Amgen

        • 14.14.1 Amgen Company Profile

        • 14.14.2 Amgen Biologics (Biosimilar) Market Performance

        • 14.14.3 Product&Service Introduction

      • 14.15 Roche

        • 14.15.1 Roche Company Profile

        • 14.15.2 Roche Biologics (Biosimilar) Market Performance

        • 14.15.3 Product&Service Introduction

      • 14.16 CP Guojian Pharmacy

        • 14.16.1 CP Guojian Pharmacy Company Profile

        • 14.16.2 CP Guojian Pharmacy Biologics (Biosimilar) Market Performance

        • 14.16.3 Product&Service Introduction

    Chapter 15 Research Conclusions and Investment Suggestions

    • 15.1 Biologics (Biosimilar) Industry Research Conclusions

    • 15.2 Biologics (Biosimilar) Industry Investment Suggestions

      • 15.2.1 Suggestions on Industry Development Strategy

      • 15.2.2 Suggestions on Industry Investment Direction

      • 15.2.3 Suggestions on Industry Investment Strategy


    List of Tables and Figures

    • Figure China Biologics (Biosimilar) Industry Market Size (2018-2029)

    • Figure China Biologics (Biosimilar) Production Volume, Production Value and Growth Rate of Recombinant Non-glycosylated Proteins (2018-2029)

    • Figure China Biologics (Biosimilar) Production Volume, Production Value and Growth Rate of Recombinant Glycosylated Proteins (2018-2029)

    • Figure China Biologics (Biosimilar) Sales Volume, Sales Value and Growth Rate of Chronic and Autoimmune Disorders (2018-2029)

    • Figure China Biologics (Biosimilar) Sales Volume, Sales Value and Growth Rate of Blood Disorders (2018-2029)

    • Figure China Biologics (Biosimilar) Sales Volume, Sales Value and Growth Rate of Others (2018-2029)

    • Figure China Biologics (Biosimilar) Sales Volume, Sales Value and Growth Rate of Oncology (2018-2029)

    • Figure China Biologics (Biosimilar) Sales Volume, Sales Value and Growth Rate of Growth Hormonal Deficiency (2018-2029)

    • Figure North China Biologics (Biosimilar) Market Size and Growth Rate from 2018-2029

    • Figure Central China Biologics (Biosimilar) Market Size and Growth Rate from 2018-2029

    • Figure South China Biologics (Biosimilar) Market Size and Growth Rate from 2018-2029

    • Figure East China Biologics (Biosimilar) Market Size and Growth Rate from 2018-2029

    • Figure Northeast China Biologics (Biosimilar) Market Size and Growth Rate from 2018-2029

    • Figure Southwest China Biologics (Biosimilar) Market Size and Growth Rate from 2018-2029

    • Figure Northwest China Biologics (Biosimilar) Market Size and Growth Rate from 2018-2029

    • Figure Biologics (Biosimilar) Industry Chain

    • Table Product Types of Major Suppliers in 2023

    • Figure China Biologics (Biosimilar) Market Share by Type in 2018

    • Figure China Biologics (Biosimilar) Market Share by Type in 2023

    • Figure China Biologics (Biosimilar) Total Production Volume and Growth Rate from Production Side (2018-2023)

    • Figure China Biologics (Biosimilar) Production Volume and Growth Rate of Recombinant Non-glycosylated Proteins (2018-2023)

    • Figure China Biologics (Biosimilar) Production Volume and Growth Rate of Recombinant Glycosylated Proteins (2018-2023)

    • Figure China Biologics (Biosimilar) Market Share by Application in 2018

    • Figure China Biologics (Biosimilar) Market Share by Application in 2023

    • Figure China Biologics (Biosimilar) Total Market Size and Growth Rate from Consumption End

    • Figure China Biologics (Biosimilar) Market Size and Growth Rate of Chronic and Autoimmune Disorders (2018-2023)

    • Figure China Biologics (Biosimilar) Market Size and Growth Rate of Blood Disorders (2018-2023)

    • Figure China Biologics (Biosimilar) Market Size and Growth Rate of Others (2018-2023)

    • Figure China Biologics (Biosimilar) Market Size and Growth Rate of Oncology (2018-2023)

    • Figure China Biologics (Biosimilar) Market Size and Growth Rate of Growth Hormonal Deficiency (2018-2023)

    • Table China Biologics (Biosimilar) Production Volume by Region (2018-2023)

    • Table China Biologics (Biosimilar) Production Volume Share by Region (2018-2023)

    • Figure China Biologics (Biosimilar) Production Volume Share by Region (2018-2023)

    • Table China Biologics (Biosimilar) Production Value by Region (2018-2023)

    • Table China Biologics (Biosimilar) Production Value Share by Region (2018-2023)

    • Figure China Biologics (Biosimilar) Production Value Share by Region (2018-2023)

    • Table China Biologics (Biosimilar) Sales Volume by Region (2018-2023)

    • Table China Biologics (Biosimilar) Sales Volume Share by Region (2018-2023)

    • Figure China Biologics (Biosimilar) Sales Volume Share by Region (2018-2023)

    • Table China Biologics (Biosimilar) Sales Value by Region (2018-2023)

    • Table China Biologics (Biosimilar) Sales Value Share by Region (2018-2023)

    • Figure China Biologics (Biosimilar) Sales Value Share by Region (2018-2023)

    • Table North China Biologics (Biosimilar) Production Volume by Type (2018-2023)

    • Table North China Biologics (Biosimilar) Production Volume Share by Type (2018-2023)

    • Figure North China Biologics (Biosimilar) Production Volume Share by Type (2018-2023)

    • Table North China Biologics (Biosimilar) Sales Volume by Application (2018-2023)

    • Table North China Biologics (Biosimilar) Sales Volume Share by Application (2018-2023)

    • Figure North China Biologics (Biosimilar) Sales Volume Share by Application (2018-2023)

    • Table Central China Biologics (Biosimilar) Production Volume by Type (2018-2023)

    • Table Central China Biologics (Biosimilar) Production Volume Share by Type (2018-2023)

    • Figure Central China Biologics (Biosimilar) Production Volume Share by Type (2018-2023)

    • Table Central China Biologics (Biosimilar) Sales Volume by Application (2018-2023)

    • Table Central China Biologics (Biosimilar) Sales Volume Share by Application (2018-2023)

    • Figure Central China Biologics (Biosimilar) Sales Volume Share by Application (2018-2023)

    • Table South China Biologics (Biosimilar) Production Volume by Type (2018-2023)

    • Table South China Biologics (Biosimilar) Production Volume Share by Type (2018-2023)

    • Figure South China Biologics (Biosimilar) Production Volume Share by Type (2018-2023)

    • Table South China Biologics (Biosimilar) Sales Volume by Application (2018-2023)

    • Table South China Biologics (Biosimilar) Sales Volume Share by Application (2018-2023)

    • Figure South China Biologics (Biosimilar) Sales Volume Share by Application (2018-2023)

    • Table East China Biologics (Biosimilar) Production Volume by Type (2018-2023)

    • Table East China Biologics (Biosimilar) Production Volume Share by Type (2018-2023)

    • Figure East China Biologics (Biosimilar) Production Volume Share by Type (2018-2023)

    • Table East China Biologics (Biosimilar) Sales Volume by Application (2018-2023)

    • Table East China Biologics (Biosimilar) Sales Volume Share by Application (2018-2023)

    • Figure East China Biologics (Biosimilar) Sales Volume Share by Application (2018-2023)

    • Table Northeast China Biologics (Biosimilar) Production Volume by Type (2018-2023)

    • Table Northeast China Biologics (Biosimilar) Production Volume Share by Type (2018-2023)

    • Figure Northeast China Biologics (Biosimilar) Production Volume Share by Type (2018-2023)

    • Table Northeast China Biologics (Biosimilar) Sales Volume by Application (2018-2023)

    • Table Northeast China Biologics (Biosimilar) Sales Volume Share by Application (2018-2023)

    • Figure Northeast China Biologics (Biosimilar) Sales Volume Share by Application (2018-2023)

    • Table Southwest China Biologics (Biosimilar) Production Volume by Type (2018-2023)

    • Table Southwest China Biologics (Biosimilar) Production Volume Share by Type (2018-2023)

    • Figure Southwest China Biologics (Biosimilar) Production Volume Share by Type (2018-2023)

    • Table Southwest China Biologics (Biosimilar) Sales Volume by Application (2018-2023)

    • Table Southwest China Biologics (Biosimilar) Sales Volume Share by Application (2018-2023)

    • Figure Southwest China Biologics (Biosimilar) Sales Volume Share by Application (2018-2023)

    • Table Northwest China Biologics (Biosimilar) Production Volume by Type (2018-2023)

    • Table Northwest China Biologics (Biosimilar) Production Volume Share by Type (2018-2023)

    • Figure Northwest China Biologics (Biosimilar) Production Volume Share by Type (2018-2023)

    • Table Northwest China Biologics (Biosimilar) Sales Volume by Application (2018-2023)

    • Table Northwest China Biologics (Biosimilar) Sales Volume Share by Application (2018-2023)

    • Figure Northwest China Biologics (Biosimilar) Sales Volume Share by Application (2018-2023)

    • Table Gelgen Biopharma Company Profile

    • Table Gelgen Biopharma Biologics (Biosimilar) Revenue, Price and Gross (2018-2023)

    • Table Mylan Company Profile

    • Table Mylan Biologics (Biosimilar) Revenue, Price and Gross (2018-2023)

    • Table Sanofi Company Profile

    • Table Sanofi Biologics (Biosimilar) Revenue, Price and Gross (2018-2023)

    • Table Biotech Pharma Company Profile

    • Table Biotech Pharma Biologics (Biosimilar) Revenue, Price and Gross (2018-2023)

    • Table Sandoz Company Profile

    • Table Sandoz Biologics (Biosimilar) Revenue, Price and Gross (2018-2023)

    • Table Merck Company Profile

    • Table Merck Biologics (Biosimilar) Revenue, Price and Gross (2018-2023)

    • Table Johnson & Johnson Company Profile

    • Table Johnson & Johnson Biologics (Biosimilar) Revenue, Price and Gross (2018-2023)

    • Table Hospira Company Profile

    • Table Hospira Biologics (Biosimilar) Revenue, Price and Gross (2018-2023)

    • Table Lilly Company Profile

    • Table Lilly Biologics (Biosimilar) Revenue, Price and Gross (2018-2023)

    • Table 3sbio Company Profile

    • Table 3sbio Biologics (Biosimilar) Revenue, Price and Gross (2018-2023)

    • Table AbbVie Company Profile

    • Table AbbVie Biologics (Biosimilar) Revenue, Price and Gross (2018-2023)

    • Table Pfizer Company Profile

    • Table Pfizer Biologics (Biosimilar) Revenue, Price and Gross (2018-2023)

    • Table Novartis Company Profile

    • Table Novartis Biologics (Biosimilar) Revenue, Price and Gross (2018-2023)

    • Table Amgen Company Profile

    • Table Amgen Biologics (Biosimilar) Revenue, Price and Gross (2018-2023)

    • Table Roche Company Profile

    • Table Roche Biologics (Biosimilar) Revenue, Price and Gross (2018-2023)

    • Table CP Guojian Pharmacy Company Profile

    • Table CP Guojian Pharmacy Biologics (Biosimilar) Revenue, Price and Gross (2018-2023)


Report Version Choose

Report

BUY NOW

Our Customers

Beyond grateful for the confidence and support from all partners and customers.A win-win situation is our ultimate pursuit.

Beyond Consulting, Future is Feasible

We provide more professional and intelligent market reports to complement your business decisions.

CONTACT US